Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

It is alarming to note that as per UNAIDS data the annual number of new HIV infections in the Latin American countries ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close.

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Since the initial release of Open AI’s Chat GPT in 2022, the adoption of artificial intelligence (AI) technology has spread across the world, growing to encompass every industry thanks to its ability ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...